Strategic Partnership WHPM has recently partnered with DanceSafe to launch a rapid, low-cost xylazine test strip, signaling openness to co-development and distribution partnerships in the harm reduction and diagnostics space.

Regulatory Capabilities As a GMP-certified facility for in vitro diagnostic medical devices, WHPM offers a credible manufacturing and regulatory-compliant foundation ideal for OEM collaborations, contract manufacturing, or white-label rapid test solutions.

Midmarket Footprint With 11–50 employees and annual revenue in the 10–25 million range, WHPM represents a lean, growth-oriented potential partner or customer for scalable manufacturing services, component supply, or technology licensing.

Rapid Test Focus WHPM’s specialization in one-step rapid membrane tests and its immunoassay capabilities indicate strong potential for new product development, expanded test panels, and cross-sell of related rapid diagnostics components or platforms.

Strategic Proximity Headquartered near Los Angeles, WHPM is positioned to leverage regional logistics, distribution partnerships, and proximity to West Coast healthcare providers and research institutions for pilots, field trials, and channel expansion.